Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Notes Payables (2016 - 2021)

Sunshine Biopharma (SBFM) has disclosed Notes Payables for 8 consecutive years, with $1.9 million as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Notes Payables rose 131.58% year-over-year to $1.9 million, compared with a TTM value of $1.9 million through Dec 2021, up 131.58%, and an annual FY2021 reading of $1.9 million, up 131.58% over the prior year.
  • Notes Payables was $1.9 million for Q4 2021 at Sunshine Biopharma, up from $330000.0 in the prior quarter.
  • Across five years, Notes Payables topped out at $1.9 million in Q4 2021 and bottomed at $1012.0 in Q2 2018.
  • Average Notes Payables over 5 years is $482393.5, with a median of $419663.0 recorded in 2018.
  • The sharpest move saw Notes Payables plummeted 99.47% in 2018, then surged 67980.73% in 2019.
  • Year by year, Notes Payables stood at $516867.0 in 2017, then dropped by 18.81% to $419663.0 in 2018, then soared by 39.71% to $586307.0 in 2019, then soared by 39.94% to $820454.0 in 2020, then surged by 131.58% to $1.9 million in 2021.
  • Business Quant data shows Notes Payables for SBFM at $1.9 million in Q4 2021, $330000.0 in Q2 2021, and $143661.0 in Q1 2021.